* If you want to update the article please login/register
Health care professionals have a higher risk of viruses and the influenza virus can infect vulnerable patients who are susceptible to severe disease and mortality. Among Jordanian HCWs during the last influenza season in 2021/2022, the aim of the current study was to determine the prevalence of influenza vaccine acceptance and uptake, as well as its determinants. Using the recently validated 5C scale questionnaire and the vaccine conspiracy belief scale, psychological factors of influenza vaccine acceptance and vaccination conspiracy theories were investigated. In the last influenza season, the self-reported uptake of the influenza vaccine was 58%. The most significant factors for vaccination acceptance and uptake were behavioural determinants, although general vaccine conspiracy theories appeared to be the most influential factors for vaccination acceptance and uptake, though more recent influenza vaccination trends should be considered in educational and interventional steps aimed at increasing influenza vaccination.
Source link: https://doi.org/10.3390/vaccines10081355
Every season, the introduction of influenza seed viruses in egg culture may result in a varying antigenic vaccine match. We review the relative vaccination results of three retrospective observational cohort studies conducted during three seasons u2013-2018, 2019-2019, and 2020-2021 influenza vaccines in the United States, based on the same underlying electronic medical record database for both three seasons, with the addition of linked medical data for the first two seasons. Using diagnostic codes specific to influenza disease from the data of over ten million people, we discovered IRMEs using influenza disease-specific diagnostic codes.
Source link: https://doi.org/10.3390/vaccines10060896
We wanted to investigate the effect of obesity on quadrivalent influenza vaccine responses in children. The investigation involved children with obesity and children without obesity. The results of vaccination immunogenicity were compared between children with and without obesity. Following vaccination for each of the four influenza strains, more than 80% of the participants with and without obesity had seroprotective antibody titres at both 1 and 6 months. For all influenza vaccine strains, Influenza-specific geometric mean titres at baseline, 1, and 6 months post-vaccination were similar between children with and without obesity.
Source link: https://doi.org/10.3390/vaccines10050699
Since 2014, a large database has been integrated that links primary care electronic medical records with pharmacy and medical claims information on over 123 million U. S. patients. This article explores the key components of the Integrated Dataset and assesses its predictability to the American population and potential use in testing influenza vaccine effectiveness. Variables included in the Integrated Dataset were tested against World Health Organization defined key and non-critical variables for determining influenza vaccine results. In addition, the Integrated Dataset includes WHO key and non-critical variables for the estimation of influenza vaccine efficiency.
Source link: https://doi.org/10.3390/vaccines10050727
We developed an epitope-based universal vaccine, rMVA-k2, against the influenza virus that was based on the modified vaccinia Ankara vector and using our own algorithms to select epitopes from conserved fragments of influenza A and B's conserved fragments of the NP, M1 and HA proteins of influenza A and B. When infected with different strains of influenza A, H1N1, H3N2, and H5N1 subtypes of influenza A, double immunization protects mice with a 67% or greater risk of viral influenza pneumonia.
Source link: https://doi.org/10.3390/vaccines10040534
Standard-dose quadrivalent influenza vaccines are intended to provide protection against all four influenza strains. This report looked at the payer and societal context in Spain, determining the cost-effectiveness of aQIV vs. egg-based standard-dose QIV in the elderly population. According to the statistics, replacing QIVe with aQIV in the Spanish elderly population would prevent on average 43,664 influenza-related deaths, 1111 hospitalizations, 569 hospitalizations, and 252 deaths. The incremental cost per quality adjusted life years gained by aQIV are 34. 6%, according to the payer; from a societal perspective, aQIV was cost-saving relative to QIVe. Results show that replacing QIVe with aQIV in the Spanish elderly population is a cost-effective solution for the Spanish healthcare system.
Source link: https://doi.org/10.3390/vaccines10081360
We investigated the immunological differences between two types of vaccinations – one from the Middle East respiratory syndrome virus and inactivated influenza virus vaccine — in combination with a single-stranded RNA adjuvant, u2014administered via various routes to BALB/c mice. In summary, the inoculation route should be tailored to eliciting a humoral immune response, whereas the intranasal route is suitable for T-cell activation and IgA induction.
Source link: https://doi.org/10.3390/pharmaceutics12050441
paraphrase influenza vaccinations are required for horses within 6 months and 21 days of competing. The international governing body of equestrian sports has mandated that horses be immunized against equine influenza within 6 months and 21 days of competing. The aim of this study was to compare the antibody responses of young sport horses to six-month booster vaccination with equine influenza vaccines of various formulations. An inactivated vaccine was given to 35 horses, and subunit and recombinant vaccines were given to 34 horses per. Whole blood samples were obtained at the time of vaccination and on nine occasions up to six months and 21 days post vaccination, with nine of them up to six months and 21 days post vaccination. paraphrase influenza antibodies were characterized by single radial haemolysis. Only two horses failed to seroconvert post booster vaccination, but there was a delay in the introduction of the recombinant vaccine. The antibody response to the recombinant vaccine was lower than that produced by whole-inactivated and subunit vaccinations up to three months after vaccination, according to the article.
Source link: https://doi.org/10.3390/vaccines8030372
Via the P2A self-cleavage website, we used live attenuated influenza virus vector to produce recombinant influenza viruses expressing a variety of T-cell epitopes of SARS-CoV-2 from either neuraminidase or non-structural genes. Despite the immunodominance of NP 366 influenza T-cell epitope, human leukocyte antigen-A*0201 transgenic mice with these recombinant viruses did not result in significant SARS-CoV-2-specific T-cell responses, as shown by human leukocyte antigen-A*0201 transgenic mice with these recombinant viruses. However, covalent virus- and LAIV vector stimulation of peripheral blood mononuclear cells in samples stimulated with LAIV/SARS-CoV-2 stimulated memory T cells in samples, but not LAIV alone. Overall, LAIV is a promising platform for the creation of a bivalent vaccine against influenza and SARS-CoV-2.
Source link: https://doi.org/10.3390/vaccines10071142
In healthy people 18 to 36 years old, we carried out a phase 1 trial to determine the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant at different doses combined with trivalent influenza vaccine in healthy people 18 to 203050 years old. The IL-10 ratio was measured, and Hemagglutination-inhibition assays, antibody to Influenza A virus nucleoprotein, and peripheral blood mononuclear cells for measurement of interferon-gamma ELISPOT responses to influenza antigens, Granzyme B and IFN were tested. In doses of 30 to 240 u00b5g performed with reduced influenza antigen levels, there was no signs up to three years after vaccination.
Source link: https://doi.org/10.3390/vaccines8030393
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions